Nabriva Therapeutics to Present at the H.C. Wainwright BioConnect Virtual Conference

Rhea-AI Summary

Nabriva Therapeutics (NASDAQ: NBRV) recently announced that CEO Ted Schroeder will present a company overview at the H.C. Wainwright BioConnect Virtual Conference, starting January 10, 2022, at 7:00 AM ET. The presentation will be available on-demand and can be accessed via the Investors section of the Nabriva website. Management will also host investor meetings from January 10-13, 2022. The company specializes in developing innovative anti-infective agents, including XENLETA® and CONTEPO™, aimed at treating serious infections.

News Market Reaction – NBRV

-3.31%

-3.31% Session move

In the trading session that priced this news, NBRV declined 3.31%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

DUBLIN, Ireland and FORT WASHINGTON, Pa., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Ted Schroeder, Chief Executive Officer at Nabriva, will provide a company overview and business update at the H.C. Wainwright BioConnect Virtual Conference. The presentation will be available on-demand beginning on Monday, January 10 at 7:00am ET. Management will also host investor meetings January 10-13, 2022.

The presentation may be accessed by visiting the "Investors" section of the Company's website under the "Events and Presentations" tab at www.nabriva.com. A replay of the webcast will be available for 90 days.

About Nabriva Therapeutics plc

Nabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections. Nabriva Therapeutics received U.S. Food and Drug Administration approval for XENLETA® (lefamulin injection, lefamulin tablets), the first systemic pleuromutilin antibiotic for community-acquired bacterial pneumonia (CABP). Nabriva Therapeutics is also developing CONTEPO™ (fosfomycin) for injection, a potential first-in-class epoxide antibiotic for complicated urinary tract infections (cUTI), including acute pyelonephritis. Nabriva entered into an exclusive agreement with subsidiaries of Merck & Co. Inc., Kenilworth, N.J., USA to market, sell and distribute SIVEXTRO® (tedizolid phosphate) in the United States and certain of its territories.

CONTACTS:

For Investors
Kim Anderson
Nabriva Therapeutics plc
ir@nabriva.com 

For Media
Andrea Greif
Ogilvy
andrea.greif@ogilvy.com 
914-772-3027

FAQ

What is the date of Nabriva Therapeutics' presentation at the H.C. Wainwright BioConnect Virtual Conference?

Nabriva Therapeutics' presentation will take place on January 10, 2022, at 7:00 AM ET.

How can I access the Nabriva Therapeutics presentation?

The presentation can be accessed on-demand in the Investors section of Nabriva Therapeutics' website starting January 10, 2022.

What are Nabriva Therapeutics' key products mentioned in the press release?

Nabriva Therapeutics' key products include XENLETA® and CONTEPO™.

When will investor meetings for Nabriva Therapeutics occur?

Investor meetings for Nabriva Therapeutics will occur from January 10-13, 2022.

What is the main focus of Nabriva Therapeutics?

Nabriva Therapeutics focuses on the commercialization and development of innovative anti-infective agents to treat serious infections.